{"schema_version":"secwatch.filing_event.v1","accession":"0001217234-23-000224","form_type":"8-K","ticker":"CDNA","cik":"0001217234","company_name":"CareDx, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.449294+00:00","generated_at":"2026-06-08T08:44:28.795194+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CareDx Q3 revenue $67.2M (-15% YoY); net loss $23.5M; raises FY2023 guidance to $274-278M","bullets":["Revenue $67.2M (-15% YoY); testing services $47.8M (-26% YoY).","Net loss $23.5M ($0.43 loss per share) vs $16.9M loss ($0.32 loss per share) in Q3 2022; non-GAAP loss $9.6M.","Adjusted EBITDA loss $10.9M, compared to loss $2.5M in Q3 2022.","Raised full-year 2023 revenue guidance to $274-278M from prior outlook.","SEC concluded inquiry with no enforcement action; Medicare coverage for HeartCare and AlloSure Lung."],"urls":{"canonical":"https://secwatch.observer/filing/0001217234-23-000224","json":"https://secwatch.observer/filing/0001217234-23-000224.json","markdown":"https://secwatch.observer/filing/0001217234-23-000224.md","text":"https://secwatch.observer/filing/0001217234-23-000224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1217234/000121723423000224/0001217234-23-000224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1217234/000121723423000224/cdna-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:44:28.795194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02af1dde06527e23c1792accf996858f87af90b2","claim":"CareDx, Inc. reported the third quarter ended September 30, 2023 results: revenue $67.2 million, net income $23.5 million, EPS $0.43. Guidance raised.","evidence_excerpt":"for transplant patients and caregivers -- today reported financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights • Reported revenue of $67.2 million, an increase of 7% over the second quarter of 2023, excluding approximately $7.8 million related to Medicare claims billing that were held over from the first quarter of 2023 and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1217234/000121723423000224/0001217234-23-000224-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$67.2 million"},{"label":"Net income","value":"$23.5 million"},{"label":"EPS","value":"$0.43"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}